JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uhlig, S.
Right arrow Articles by Wendel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uhlig, S.
Right arrow Articles by Wendel, A.

Vol. 283, Issue 3, 1453-1459, 1997

Attenuation by Phosphodiesterase Inhibitors of Lipopolysaccharide-Induced Thromboxane Release and Bronchoconstriction in Rat Lungs1

Stefan Uhlig, Roland Lewis Featherstone, Heinz-Dieter Held, Rolf Nüsing, Christian Schudt and Albrecht Wendel

Biochemical Pharmacology, University of Konstanz, Konstanz, Germany (S.U., R.L.F., H.-D.H., A.W.); Byk Gulden, Ltd., Konstanz, Germany (C.S.); and Medical Center of Pediatrics, University Hospital Marburg, Marburg, Germany (R.N.)

Exposure of perfused rat lungs to lipopolysaccharides (LPS) causes induction of cyclooxygenase-2 followed by thromboxane (TX)-mediated bronchoconstriction (BC). Recently, phosphodiesterase (PDE) inhibitors have received much interest because they not only are bronchodilators but also can suppress release of proinflammatory mediators. In the present study, we investigated the effect of three different PDE inhibitors on TX release and BC in LPS-exposed perfused rat lungs. The PDE inhibitors used were motapizone (PDE III specific), rolipram (PDE IV specific), and zardaverine (mixed PDE III and IV specific). At 5 µM, a concentration at which all three compounds selectively block their respective PDE isoenzyme, rolipram (IC50 = 0.04 µM) and zardaverine (IC50 = 1.8 µM) largely attenuated the LPS-induced BC, whereas motapizone was almost ineffective (IC50 = 40 µM). In contrast to LPS, BC induced by the TX-mimetic U46619 was prevented with comparable strength by motapizone and rolipram. In LPS-treated lungs, the TX release was reduced to 50% of controls by rolipram and zardaverine but was unaltered in the presence of 5 µM motapizone. Increasing intracellular cAMP through perfusion of db-cAMP or forskolin (activates adenylate cyclase) also reduced TX release and BC. We conclude that PDE inhibitors act via elevation of intracellular cAMP. Although both PDE III and PDE IV inhibitors can relax airway smooth muscle, in the model of LPS-induced BC, PDE IV inhibitors are more effective because (in contrast to PDE III inhibitors) they also attenuate TX release.


0022-3565/97/2833-1453$03.00/0
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Eur Respir JHome page
R.T. Schermuly, H. Leuchte, H.A. Ghofrani, N. Weissmann, F. Rose, M. Kohstall, H. Olschewski, C. Schudt, F. Grimminger, W. Seeger, et al.
Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure
Eur. Respir. J., August 1, 2003; 22(2): 342 - 347.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. J. Toward and K. J. Broadley
Goblet Cell Hyperplasia, Airway Function, and Leukocyte Infiltration after Chronic Lipopolysaccharide Exposure in Conscious Guinea Pigs: Effects of Rolipram and Dexamethasone
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 814 - 821.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. J. Toward and K. J. Broadley
Chronic Lipopolysaccharide Exposure on Airway Function, Cell Infiltration, and Nitric Oxide Generation in Conscious Guinea Pigs: Effect of Rolipram and Dexamethasone
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 298 - 306.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Aoki, S. Yamamoto, M. Kobayashi, K. Ohga, H. Kanoh, K. Miyata, K. Honda, and T. Yamada
Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 165 - 173.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Ermert, M. Merkle, R. Mootz, F. Grimminger, W. Seeger, and L. Ermert
Endotoxin priming of the cyclooxygenase-2-thromboxane axis in isolated rat lungs
Am J Physiol Lung Cell Mol Physiol, June 1, 2000; 278(6): L1195 - L1203.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.